Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Protalix BioTherapeutics, Inc.AMEX: PLX

Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026

Deferred tax liabilities remains negative

Q1 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.

Context

  • Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred tax liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Tax Liabilities vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's Mar 2026 deferred tax liabilities of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
  • Deferred tax liabilities amounts to 0.0% of total assets for PLX, versus a peer median of 0.0%.
PLX Competitors Peer median
Deferred Tax Liabilities for PLX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$30M -0.2%-1.8%2.3%
PLXProtalix BioTherapeutics, Inc.Mar 2026$0 ——0.0%
PHARPharming Group N.V.Mar 2026$0 ——0.0%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding PLX) $0-0.2%-1.8%0.0%

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents38.99M17.11M23.63M19.76M14.68M
Short-term Investments05.07M20.93M15.07M15.59M
Net Receivables3.44M4.59M5.27M2.91M8.84M
Inventory17.95M16.8M19.05M21.24M25.73M
Other Current Assets380K536K611K596K1.44M
Total Current Assets61.67M44.88M69.93M60.08M66.67M
Property, Plant & Equipment (Net)9.92M9.64M10.88M10.02M12.58M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets003.09M2.86M2.52M
Other Non-current Assets2.08M1.27M528K462K578K
Total Non-current Assets12M10.91M14.5M13.34M15.67M
Total Assets73.67M55.79M84.43M73.42M82.35M
Account Payables6.99M5.86M4.32M4.53M5.26M
Short-term Debt0021.66M00
Tax Payables0530K2.88M3.48M0
Deferred Revenue8.55M13.18M000
Other Current Liabilities1.51M11.06M4.94M1.81M2.31M
Total Current Liabilities33.18M32.43M45.53M25.62M26.52M
Long-term Debt27.89M28.19M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)11.79M0000
Other Non-current Liabilities2.47M1.64M714K559K661K
Total Non-current Liabilities46.53M34M5.34M4.59M7.6M
Total Liabilities79.7M66.43M50.87M30.21M34.12M
Common Stock46K54K73K76K80K
Retained Earnings(374.93M)(389.86M)(381.55M)(378.39M)(385M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(6.04M)(10.64M)33.57M43.21M48.23M
Total Debt33.47M33.47M27.69M5.53M8.32M
Net Debt(5.52M)16.36M4.06M(14.23M)(6.36M)

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.